These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32233615)

  • 1. Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment.
    Arecco L; Blondeaux E; Damassi A; Fregatti P; Lambertini M
    Ann Palliat Med; 2020 Mar; 9(2):512-516. PubMed ID: 32233615
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimizing Anti-HER2 Therapy in early breast cancer: updates from the KRISTINE trial.
    Hennessy MA; Morris PG
    Ann Palliat Med; 2020 Mar; 9(2):504-509. PubMed ID: 32233616
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial.
    Khattak MN; Chichura AM; Lang JE
    Ann Surg Oncol; 2024 Mar; 31(3):1423-1427. PubMed ID: 38127215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
    Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab emtansine: a game changer in HER2-positive early breast cancer.
    Mano M
    Future Oncol; 2020 Nov; 16(32):2595-2609. PubMed ID: 32734779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine.
    Hopkins AM; Rowland A; Logan JM; Sorich MJ
    Breast; 2019 Aug; 46():90-94. PubMed ID: 31170589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant pertuzumab plus trastuzumab or adjuvant T-DM1; Which is better?
    Altundag K
    J BUON; 2021; 26(3):1170. PubMed ID: 34268988
    [No Abstract]   [Full Text] [Related]  

  • 9. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
    Saad ED; Squifflet P; Burzykowski T; Quinaux E; Delaloge S; Mavroudis D; Perez E; Piccart-Gebhart M; Schneider BP; Slamon D; Wolmark N; Buyse M
    Lancet Oncol; 2019 Mar; 20(3):361-370. PubMed ID: 30709633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
    Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment of patients with early breast cancer: recent updates and state of the art.
    Caparica R; Brandão M; Piccart M
    Breast; 2019 Nov; 48 Suppl 1():S7-S20. PubMed ID: 31839166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.
    García-Alonso S; Ocaña A; Pandiella A
    Trends Cancer; 2020 Feb; 6(2):130-146. PubMed ID: 32061303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituting adjuvant trastuzumab emtansine for Herceptin improves survival in patients with human epidermal growth factor receptor 2-positive breast cancer.
    Printz C
    Cancer; 2019 Apr; 125(8):1213. PubMed ID: 30934124
    [No Abstract]   [Full Text] [Related]  

  • 15. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
    J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
    Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
    Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ado-trastuzumab emtansine in current clinical practice.
    Turshudzhyan A
    J Oncol Pharm Pract; 2021 Jan; 27(1):150-155. PubMed ID: 32838683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.